Page last updated: 2024-09-03

angiotensin ii, des-phe(8)- and 20-hydroxy-5,8,11,14-eicosatetraenoic acid

angiotensin ii, des-phe(8)- has been researched along with 20-hydroxy-5,8,11,14-eicosatetraenoic acid in 1 studies

Compound Research Comparison

Studies
(angiotensin ii, des-phe(8)-)
Trials
(angiotensin ii, des-phe(8)-)
Recent Studies (post-2010)
(angiotensin ii, des-phe(8)-)
Studies
(20-hydroxy-5,8,11,14-eicosatetraenoic acid)
Trials
(20-hydroxy-5,8,11,14-eicosatetraenoic acid)
Recent Studies (post-2010) (20-hydroxy-5,8,11,14-eicosatetraenoic acid)
1,5332199564013233

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carroll, MA; Chander, PN; Kang, Y; Stier, CT1

Other Studies

1 other study(ies) available for angiotensin ii, des-phe(8)- and 20-hydroxy-5,8,11,14-eicosatetraenoic acid

ArticleYear
Azilsartan is associated with increased circulating angiotensin-(1-7) levels and reduced renovascular 20-HETE levels.
    American journal of hypertension, 2015, Volume: 28, Issue:5

    Topics: Angiotensin I; Animals; Benzimidazoles; Blood Pressure; Disease Models, Animal; Hydroxyeicosatetraenoic Acids; Hypertension; Hypertension, Renovascular; Male; Oxadiazoles; Peptide Fragments; Rats; Rats, Sprague-Dawley; Vasoconstriction

2015